ID26091A - Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin - Google Patents

Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin

Info

Publication number
ID26091A
ID26091A IDW20001882A ID20001882A ID26091A ID 26091 A ID26091 A ID 26091A ID W20001882 A IDW20001882 A ID W20001882A ID 20001882 A ID20001882 A ID 20001882A ID 26091 A ID26091 A ID 26091A
Authority
ID
Indonesia
Prior art keywords
derivates
campototesin
antrasicline
composition containing
synergistic combination
Prior art date
Application number
IDW20001882A
Other languages
English (en)
Indonesian (id)
Inventor
Geroni Cristina
Ripamonti Marina
Caruso Michele
Suarato Antonino
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of ID26091A publication Critical patent/ID26091A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW20001882A 1998-03-24 1999-03-19 Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin ID26091A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9806324.1A GB9806324D0 (en) 1998-03-24 1998-03-24 Antitumour synergetic composition

Publications (1)

Publication Number Publication Date
ID26091A true ID26091A (id) 2000-11-23

Family

ID=10829188

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001882A ID26091A (id) 1998-03-24 1999-03-19 Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin

Country Status (29)

Country Link
US (1) US6403563B1 (cs)
EP (1) EP1067941B1 (cs)
JP (1) JP2002507571A (cs)
KR (1) KR20010034619A (cs)
CN (2) CN1150002C (cs)
AR (1) AR018166A1 (cs)
AT (1) ATE271388T1 (cs)
AU (1) AU758191B2 (cs)
BR (1) BR9908391A (cs)
CA (1) CA2324610A1 (cs)
CZ (1) CZ295368B6 (cs)
DE (1) DE69918819T2 (cs)
DK (1) DK1067941T3 (cs)
EA (1) EA003134B1 (cs)
ES (1) ES2226366T3 (cs)
GB (1) GB9806324D0 (cs)
HU (1) HUP0101615A3 (cs)
ID (1) ID26091A (cs)
IL (1) IL138035A0 (cs)
MY (1) MY133016A (cs)
NO (1) NO20004703L (cs)
NZ (1) NZ507570A (cs)
PL (1) PL343098A1 (cs)
PT (1) PT1067941E (cs)
SI (1) SI1067941T1 (cs)
TW (1) TW576740B (cs)
UA (1) UA63000C2 (cs)
WO (1) WO1999048503A1 (cs)
ZA (1) ZA992255B (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6820065B1 (en) * 1998-03-18 2004-11-16 Ascom Hasler Mailing Systems Inc. System and method for management of postage meter licenses
GB9904387D0 (en) * 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB9909925D0 (en) 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
GB9916882D0 (en) * 1999-07-19 1999-09-22 Pharmacia & Upjohn Spa Antitumor synergistic composition
GB9926843D0 (en) * 1999-11-12 2000-01-12 Pharmacia & Upjohn Spa Lipid complex of alkycyclines
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
EP1985286A1 (en) * 2007-04-24 2008-10-29 Biocompatibles UK Limited Microspheres for treatment of brain tumours
US8349764B2 (en) 2007-10-31 2013-01-08 Molycorp Minerals, Llc Composition for treating a fluid
US20090107925A1 (en) * 2007-10-31 2009-04-30 Chevron U.S.A. Inc. Apparatus and process for treating an aqueous solution containing biological contaminants
US20110207760A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Sn-38 compositions
EP3012329B1 (en) 2010-06-18 2017-10-25 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
US9233863B2 (en) 2011-04-13 2016-01-12 Molycorp Minerals, Llc Rare earth removal of hydrated and hydroxyl species
EP2721181B1 (en) 2011-06-17 2019-12-18 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
WO2013096843A1 (en) 2011-12-21 2013-06-27 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
CA3126823C (en) 2012-06-07 2023-04-04 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
ES2777228T3 (es) 2013-04-05 2020-08-04 Myriad Genetics Inc Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer
EP4023765A1 (en) 2013-12-09 2022-07-06 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
KR20160132076A (ko) 2014-03-07 2016-11-16 몰리코프 미네랄스, 엘엘씨 비소 제거 특성이 뛰어난 세륨(iv) 산화물
PT3180447T (pt) 2014-08-15 2020-06-18 Myriad Genetics Inc Métodos e materiais para avaliar a deficiência de recombinação homóloga
EP4141127B1 (en) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9114549D0 (en) * 1991-07-05 1991-08-21 Erba Carlo Spa Mono and bis alkylamino-anthracyclines
GB9325417D0 (en) * 1993-12-13 1994-02-16 Erba Carlo Spa 3'- aziridino-anthracycline derivatives

Also Published As

Publication number Publication date
JP2002507571A (ja) 2002-03-12
EP1067941A1 (en) 2001-01-17
ES2226366T3 (es) 2005-03-16
KR20010034619A (ko) 2001-04-25
DE69918819T2 (de) 2005-08-18
US6403563B1 (en) 2002-06-11
DK1067941T3 (da) 2004-11-29
PT1067941E (pt) 2004-12-31
IL138035A0 (en) 2001-10-31
WO1999048503A1 (en) 1999-09-30
UA63000C2 (en) 2004-01-15
NO20004703D0 (no) 2000-09-20
AU758191B2 (en) 2003-03-20
NO20004703L (no) 2000-09-20
SI1067941T1 (en) 2005-02-28
CZ295368B6 (cs) 2005-07-13
GB9806324D0 (en) 1998-05-20
CZ20003493A3 (cs) 2001-02-14
BR9908391A (pt) 2000-10-31
ATE271388T1 (de) 2004-08-15
NZ507570A (en) 2003-01-31
TW576740B (en) 2004-02-21
CN1528334A (zh) 2004-09-15
EA200000978A1 (ru) 2001-02-26
EP1067941B1 (en) 2004-07-21
HUP0101615A2 (hu) 2001-10-28
EA003134B1 (ru) 2003-02-27
MY133016A (en) 2007-10-31
DE69918819D1 (de) 2004-08-26
AU3331499A (en) 1999-10-18
ZA992255B (en) 1999-10-05
PL343098A1 (en) 2001-07-30
CA2324610A1 (en) 1999-09-30
AR018166A1 (es) 2001-10-31
HUP0101615A3 (en) 2002-12-28
CN1294516A (zh) 2001-05-09
CN1150002C (zh) 2004-05-19

Similar Documents

Publication Publication Date Title
ID26091A (id) Komposisi antitumor yang mengandung gabungan sinergistik dari derivat antrasiklin dengan derivat kamptotesin
PT1049467E (pt) Composicoes de celecoxib
PT2270173E (pt) Composições de neisseria de combinação
DK2301541T3 (da) Antibiotiske sammensætninger til behandling af øjet
PT1165069E (pt) Composicao sinergistica antitumoral
DE60234212D1 (de) Farbeffekt zusammensetzungen
DE60016727D1 (de) Mehrkomponentenbleichmittelzusammensetzungen
PL330949A1 (en) Antibacterial compositions
PL373562A1 (en) Color compositions
HUP0004905A3 (en) Synergistic biocide composition
EP1320385A4 (en) COMBINATION COMPOSITIONS
GB9725387D0 (en) Oxygen-scavenging compositions
HUP0104413A3 (en) Topical compositions comprising ascomycins
GB9802041D0 (en) Complexing compositions
HUP0102520A3 (en) Sweetener compositions
GB0212605D0 (en) Stabilising composition
GB2339693B (en) Anti-mollusc compositions
GB9827291D0 (en) Compositions
GB0108133D0 (en) Substituted polycyclic compounds
GB9822158D0 (en) Compositions
GB2336535B (en) Compositions
GB9809347D0 (en) Compositions
GB0103368D0 (en) Organic compositions
GB9818278D0 (en) Compositions
GB9815234D0 (en) Organic compositions